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Abstract
Background: First dose observation for cardiac effects is required for fingolimod, but recommendations on the
extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic episodes
were evaluated to assess the relevance of continuous electrocardiogram (ECG) monitoring.
Methods: START is an ongoing open-label, multi-center study. At the time of analysis 3951 patients were enrolled.
The primary endpoints are the incidence of bradycardia (heart rate < 45 bpm) and second-/third-degree AV blocks
during treatment initiation. The relevance of Holter was assessed by matching ECG findings with the occurrence of
clinical symptoms as well as by rigorous analysis of AV blocks with regard to the duration of pauses and the
minimal heart rate recorded during AV block.
Results: Thirty-one patients (0.8%) developed bradycardia (<45 bpm), 62 patients (1.6%) had second-degree Mobitz
I and/or 2:1 AV blocks with a lowest reading (i.e. mean of ten consecutive beats) of 35 bpm and the longest pause
lasting for 2.6 s. No Mobitz II or third-degree AV blocks were observed. Only one patient complained about mild
chest discomfort and fatigue. After 1 week, there was no second-/third-degree AV block.
Conclusions: Continuous Holter ECG monitoring in this large real-life cohort revealed that bradycardia and AV
conduction abnormalities were rare, transient and benign. No further unexpected abnormalities were detected.
The data presented here give an indication that continuous Holter ECG monitoring does not add clinically relevant
value to patients’ safety.
Trial registration: NCT01585298; registered April 23, 2012.
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Background
Fingolimod (FTY720, brand name Gilenya®) has been
approved for the treatment of relapsing remitting
multiple sclerosis (RRMS). It exerts its therapeutic effects
via modulation of sphingosine-1-phosphate (S1P-) recep-
tors on lymphocytes, which results in the retention of
circulating lymphocytes in the lymph nodes [1–4]. As a
result, peripheral blood lymphocyte counts are reversibly
reduced to approximately 30%, which is postulated to
reduce recirculation of autoreactive lymphocytes and to
prevent infiltration into the central nervous system [5, 6].
Receptors of this class, predominantly S1P1, are also
expressed on atrial myocytes [7]. Fingolimod binding to
S1P1 mediates a decrease in heart rate and prolongation of
atrioventricular (AV) conduction. These effects are transi-
ent as fingolimod also induces internalization of these
receptors, causing functional antagonism. Consequently,
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the negative chronotropic effects are limited to treatment
initiation [6, 8–10].
A first-dose observation procedure is recommended.
The exact procedure is defined by local product labels and
differs between countries. It is generally required to
observe patients for bradycardia by hourly measurements
of pulse and blood pressure for at least six hours and to
obtain an electrocardiogram (ECG) prior to dosing and at
the end of the observation period. In contrast to the
United States (US) and the Australian labels, the European
Union (EU) label additionally recommends a continuous
Holter ECG for six hours. In Japan, continuous ECG and
observation of heart rate and blood pressure for 24 hours
are recommended.
START is a prospective study designed to assess the
cardiac safety of fingolimod first dose in detail and in a
much larger cohort compared to previous studies. Patients
and study sites were selected to closely resemble the broad
range of fingolimod patients and treatment circumstances
in daily practice. The study follows the EU label recom-
mendations by obtaining a Holter ECG for six hours in
addition to clinical monitoring and pre-/post first dose
ECG. Therefore, START is the first interventional study
that investigates in a large cohort whether continuous
ECG monitoring detects clinically meaningful findings
beyond pre-/post first dose ECG. The results might
facilitate guidance on the degree of observation that is
necessary to ensure patient safety.
Methods
Study design
START (NCT01585298) is an ongoing open-label, multi-
center study in Germany in patients with RRMS receiving
fingolimod at a daily dose of 0.5 mg. Its purpose is (a) to
assess cardiac safety of fingolimod first dose with a special
focus on bradycardia and AV conduction abnormalities,
and (b) to analyze individual arrhythmic episodes more
extensively in order to evaluate the clinical relevance of
continuous ECG monitoring. Up to 7000 patients are
planned to be enrolled based on a two-sided 95% confi-
dence interval with a precision of 0.23%. Sample size cal-
culation was based on the observed incidence of 0.963%
of second-degree or higher AV blocks in the first 1000
patients enrolled. Annual interim analyses are planned per
protocol to review whether the sample size needs to be
adjusted. The results of the 2015 interim analysis are re-
ported here. At the time of the interim analysis, the num-
ber of patients included has largely exceeded the sample
size of previous studies, thereby adding significantly to the
state of knowledge on the cardiac effects of fingolimod.
Endpoints
The primary endpoints are the incidence of bradycardia,
defined as heart rate < 45 bpm, and the incidence of
second- and third-degree AV blocks during the six-hour
monitoring period. For this analysis, three types of
second-degree blocks were distinguished: Mobitz type I
(progressive prolongation of the PR interval with the
subsequent occurrence of a single non-conducted P wave,
i.e. atrial impulse that creates a pause), 2:1 (second-degree
block with a fixed 2:1 ratio of conducted and non-
conducted P waves, that can be the result of either Mobitz
I or Mobitz II type blocks) or Mobitz type II (constant PR
interval followed by a non-conducted P wave, such that
either an occasional dropped P wave or a regular conduc-
tion pattern of 2:1, 3:1, and so on is observed). Secondary
endpoints include the incidence of other conduction
abnormalities such as first-degree AV block (PR-interval
prolongation), and QTc prolongation. The latter is defined
as QTc > 450 ms in males and > 470 ms in females.
Additionally, QTc prolongations > 500 ms are identified as
these patients required overnight monitoring as specified
by the EU label.
To analyze the incidence of bradycardia, pulse palpation
by study personnel was used. In detail, study personnel
were advised to measure the heart rate for at least 15 s.
Second- and third-degree AV blocks were identified from
continuous Holter ECG recordings. The remaining vari-
ables, i.e. PR- and QT-interval, were taken from 12-lead
ECG data. Fridericia formula was used for correction of the
QT intervals.
Safety assessments
The incidence of adverse events (AE) and serious adverse
events (SAE) was determined applying the definitions and
standards of the ICH guideline on clinical safety data man-
agement. Further, the incidence of AE suggestive for cardiac
events was determined using the following MedDRA pre-
ferred terms: Angina pectoris, chest discomfort, dizziness,
dyspnoea, exertional dyspnoea, fatigue, palpitations, syn-
cope, vertigo, positional vertigo, and blurred vision.
The incidence of overnight hospitalization was defined
as the number of patients who experienced a cardiac AE
(any AE out of the system organ class “cardiac disor-
ders”) starting on the day of the first fingolimod intake
and who were hospitalized for this event.
Clinical relevance of continuous ECG monitoring
To assess the relevance of continuous ECG monitoring,
the identified second-degree AV blocks were assessed for
clinical relevance, i.e. the occurrence of any cardiac symp-
toms in these patients. Furthermore, continuous ECG
recordings of patients with AV blocks were evaluated
rigorously. The duration of pauses (RR intervals) and the
minimal heart rate during second-degree AV blocks were
determined post hoc by the cardiologist. The minimal
heart rate during AV blocks was defined as the mean heart
rate of 10 beats during an AV block to detect short lasting
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changes in heart rate. Holter ECG data of patients with
cardiac symptoms were assessed for any abnormalities
that might have predicted the symptoms. Alignment of
evaluations of bradycardia as assessed by study nurse and
the Holter ECG were also evaluated post hoc. No statis-
tical comparison between Holter ECG and 12-lead ECG
plus pulse palpation assessment with respect to the inci-
dence of cardiac events was performed.
Results of START were analyzed descriptively. Where
indicated, statistical tests were performed based on
Student’s t-test unless otherwise noted.
Approval and participants
The study protocol was approved by the respective state
and institutional ethical standards committees at all
participating sites (Competent ethics committee: Ethik-
kommission der Ärztekammer Nordrhein; EUDRACT
No. 2012-000653-32-DE). Patients have to give written
informed consent. The inclusion and exclusion criteria
were defined to select patients with RRMS who were eli-
gible for treatment with fingolimod (Gilenya®) according
to the EU label. Patients were excluded if they received
class Ia or III antiarrythmic drugs or beta blockers,
heart-rate-lowering calcium channel blockers or other
substances which may decrease heart rate (e.g. digoxin,
anticholinesteratic agents or pilocarpine). Furthermore,
patients were excluded if they have a history of second-
degree Mobitz Type II or higher-degree AV block, Sick-
sinus syndrome, Sino-atrial heart block, significant QT
prolongation, symptomatic bradycardia or recurrent syn-
cope, known ischemic heart disease, cerebrovascular dis-
ease, myocardial infarction, hypokalemia, congestive
heart failure, cardiac arrest, uncontrolled hypertension,
or severe sleep apnea.
Study procedures
Patients’ eligibility was determined during a 4-week
screening phase (visit 1). At the first-dose visit (visit 2),
patients underwent baseline assessments of basic demo-
graphic and relevant clinical characteristics including MS
status, concomitant medication, vital signs, blood count
and blood chemistry. A 12-lead ECG prior to the first dose
of fingolimod was recorded. After the first intake of the
study drug, patients were monitored for six hours by
continuous Holter ECG recording, while heart rate and
blood pressure were measured simultaneously, every hour.
Afterwards, a second 12-lead ECG was recorded. The
6-hour monitoring period reflects the current EU label
and was considered sufficient as the nadir of the heart rate
decrease usually occurs four hours post-dose [9]. At visit
3, i.e. 1 week after study drug initiation, a third 12-lead
ECG is recorded and vital signs, blood count and blood
chemistry were assessed (Fig. 1). Adverse events were
recorded at all visits.
If the patient’s heart rate at the end of the 6-hour period is
the lowest following first dose administration, the monitor-
ing had to be extended by at least two hours and until the
heart rate rises. In those patients with evidence of clinically
important cardiac events (e.g. persistent new-onset second-
degree or third-degree AV block, heart rate < 45 bpm at six
hours after first dose, QTc interval ≥ 500 msec), monitoring
had to be extended until full resolution of symptoms,
including overnight monitoring. If a patient required
pharmacologic intervention during the first dose observa-
tion, the first dose monitoring strategy had to be repeated
after the second dose of fingolimod. Study medication had
to be interrupted or discontinued in cases of atypical neuro-
logical deterioration, lymphopenia < 200/μl, and a more than
5-fold elevation of liver function tests. In other cases the de-
cision on continuation of study drug was at the discretion of
the physician and the patient.
Each study site was equipped with the ECG-device Cardi-
oMem® CM3000-12, a 12-lead-continuous-ECG-digital re-
corder. The ECG recordings were pseudonymized and
immediately transmitted via internet to the cardiology read-
ing center for evaluation. The results of ECG analysis were
available to the treating physician within less than 40 min.
To identify AV blocks all Holter ECG recordings were
assessed according to the same automated analysis process.
Subsequently, two independent cardiologists manually
reviewed every second- or third-degree AV block episode
to determine the exact AV block subtype per episode, the
number of episodes, the duration of the longest pause and
the minimal heart rate (mean of ten consecutive beats).
Twice a year, an external and independent Data Safety
Monitoring Board (DSMB), consisting of two neurologists
and a cardiologist, reviewed safety-related issues. The DSMB
was entitled to recommend changes in study conduct.
Results
Study patients and conduct
The present analysis is based on 3951 patients recruited
between June 2012 and January 2015. The majority of the
patients were seen by office-based neurologists. Baseline
demographics and MS history are presented in Tables 1
and 2. A Holter ECG was recorded at visit 2 in 3906 out
of 3951 patients who received fingolimod (Fig. 1). 25
patients had discontinued medication after the first or
second dose, and another 25 patients had discontinued
the study drug further on (Table 3). In 38 patients (0.96%)
adverse events were the primary reason for discontinu-
ation. In the remaining 12 patients abnormal laboratory
values or other reasons prompted to stop the study drug.
13 patients out of those who discontinued study drug did
not show up for visit 3 (Fig. 2). These patients were
followed-up separately confirming that they were alive
and did not suffer from cardiac sequelae.
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Changes in heart rate
Patients receiving the first dose of fingolimod experi-
enced on average a slight and transient decline in heart
rate. 87.4% of the patients reached the nadir before the
end of the 6-hour post-dose observation period. In 31
patients (0.8%) the heart rate dropped below 45 bpm.
Holter ECG confirmed 23 of the 31 cases with a heart
rate below 45 as measured by study personnel. For three
patients no Holter was available und two other patients
had an insufficient Holter ECG reading. Table 4 presents
the heart beat dynamics of patients by subgroup, i.e. by
time of the lowest heart rate measurement, by presence
of bradycardia and by presence of AV blocks.
AV conduction abnormalities
First-degree AV blocks (PR-interval > 200 ms in the ECG
assessments) occurred in 2.7% of the patients before and in
5.8% of the patients after the first dose of fingolimod. In 62
patients (1.6%) a second-degree AV block was observed.
Type 2:1 AV blocks were identified for 18 patients (Table 5).
In 16 patients the 2:1 blocks emerged from Mobitz I blocks.
In the two patients with 2:1 block not emerging from
Mobitz I, the event was limited to a single episode. No
Mobitz II second-degree AV blocks or third-degree AV
blocks occurred (Table 5). On average the first second-
degree AV blocks occurred 3.62 h after drug intake (SD
1.26, range 0.62 to 5.87). The mean minimal heart rate
during second-degree AV block as assessed by Holter
ECG (mean of ten consecutive beats) was 51.5 bpm (range
35 to 80 bpm) with no significant difference between the
two types of second-degree AV blocks, Mobitz type I and
2:1 (p = 0.235). The longest pause observed in association
with second-degree AV blocks was 2.6 s. The mean value
was 1.9 s (SD 0.3), with no difference between 2:1 and
Wenckebach-type AV blocks (p = 0.887). Heart rate
dynamics of patients with second-degree AV blocks as
measured by study personnel are shown in Fig. 3 and
Table 4.
Effects on repolarisation
The mean QTc interval in the overall population was
413.8 ms (range 352 to 470 ms) before and 417.7 ms
(range 239 to 479 ms) after first dose. Applying > 450 ms
in men and > 470 ms in women as a conservative thresh-
old, only two men and four women had QTc intervals
above their respective thresholds after fingolimod intake.
None of these patients had symptoms suggestive of car-
diac events and none required additional medication
during first dose monitoring. All of these patients were
continued on study medication. No patient had a QTc
interval exceeding 500 ms, which would have warranted
overnight monitoring as defined in the current EU label.
Adverse events and cardiac symptoms
AEs were observed in 1350 patients (34.2%) and 117
patients (2.96%) experienced SAEs (Table 6). The most
frequent types of AEs causing discontinuation of medica-
tion were cardiac, gastrointestinal, and nervous system
disorders (Table 7). Symptoms reported as AE during the
6-hour monitoring suggestive of cardiac events occurred in
120 patients (3.04%, Table 6). Holter ECG revealed no
rhythm abnormalities in these patients, as confirmed by the
cardiologist. Only one case of symptomatic second-degree
AV block (0.03%) and one case of symptomatic bradycardia
Fig. 1 Visit schedule
Table 1 Patient demographics and relevant baseline characteristics
Fingolimod 0.5 mg
(N = 3951)
Age groups in years, n (%)
18–30 880 (22.3)
> 30–40 1222 (30.9)
> 40–55 1622 (41.1)
> 55–65 208 (5.3)
> 65 18 (0.5)
Sex
Female, n (%) 2779 (70.3)
Duration of MS since first symptoms in years,
mean ± SD
10.0 ± 7.6
Number of relapses in previous year,
mean ± SD
1.6 ± 1.2
EDSS, mean ± SD 2.8 ± 1.6
DMT treatment within the last 6 months, n (%)
No 827 (20.9)
Yes 3124 (79.1)
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(0.03%) were observed (Table 2). Neither syncope nor dys-
pnoea were observed in these patients. No patient required
medical treatment for bradycardia or AV block. The patient
with the lowest heart rate measured (31 bpm) was asymp-
tomatic. In total, 42 patients (1.06%) were hospitalized over-
night due to any cardiac adverse event that started during
day 1 after first dose administration. Patient characteristics
potentially increasing the risk for cardiac events by sub-
group are presented in Table 2.
Follow up
At visit 3, first-degree AV blocks were found in 2.8% of
patients. 12-lead ECG did not reveal any second- or third-
degree AV blocks. However, since no continuous ECG was
recorded at visit 3, accidental second- or third-degree AV
blocks might have been missed. Bradycardia was present in
only two patients with heart rates of 44 bpm (51 bpm at
baseline) and 43 bpm (55 bpm at baseline). No symptoms
were associated. Only two men and one woman had QTc
intervals above the relevant thresholds (>450 and > 470 ms,
respectively). None of the patients developed clinically rele-
vant QTc interval prolongation (i.e. arrhythmias).
Discussion
The data presented here demonstrate that 0.8% patients
had bradycardia and 0.03% had symptomatic bradycardia
with mild self-limiting symptoms. Transient second-
Table 2 Patient characteristics with potential relevance for cardiac events and frequency of symptoms by subgroup
Overall population Patients with
bradycardia
Patients with
second-degree
AV block
Patients
with AE
Patients with symptoms
suggestive of cardiac
events at visit 2
Patients who
discontinued
study drug
due to AE
N = 3951 N = 31 N = 62a N = 1350 N = 120 N = 38
Demographics
Age (years), mean ± SD 39.3 ± 10.4 42.1 ± 10.9 40.4 ± 11.7 39.3 ± 10.4 39.6 ± 10.4 42.3 ± 12.4
Female, n (%) 2779 (70.3) 14 (45.2) 57 (91.9) 1023 (75.8) 96 (80.0) 29 (76.3)
Concomitant medication known to prolong QT interval:
SSRI n (%) 339 (10.1) 1 (3.2) 4 (6.5) 152 (11.3) 17 (14.2) 6 (15.8)
TCA n (%) 92 (2.3) 0 0 38 (2.8) 2 (1.7) 1 (2.6)
Amantadin n (%) 42 (1.1) 0 0 18 (1.3) 2 (1.7) 0
Carbamazepin n (%) 29 (0.7) 0 1 (1.6) 14 (1.0) 3 (2.5) 1 (2.6)
Fampridine n (%) 299 (7.6) 3 (9.7) 5 (8.1) 81 (6.0) 8 (6.7) 1 (2.6)
Heart rate at visit 2 pre-dose
Heart rate (bpm), mean ± SD 73.9 ± 10.4 59.5 ± 8.0 75.0 ± 8.5 73.4 ± 10.4 73.3 ± 11.6 75.8 ± 10.6
Blood pressure at visit 2 pre-dose
Systolic (mmHg), mean ± SD 121.8 ± 14.0 125.7 ± 20.3 117.5 ± 13.7 122.0 ± 14.1 123.9 ± 14.5 120.4 ± 15.4
Diastolic (mmHg), mean ± SD 78.5 ± 9.7 78.1 ± 13.1 75.7 ± 9.0 78.7 ± 9.8 79.9 ± 10.0 76.1 ± 11.1
Potassium levels at visit 2
< 3.5 mmol/L 13 (0.3) 0 0 5 (0.4) 0 0
≥ 3.5–5.5 mmol/L 3853 (98.3) 31 (100) 61 (98.4) 1320 (98.5) 119 (99.2) 38 (100.0)
> 5.5 mmol/L 54 (1.4) 0 1 (1.6) 15 (1.1) 1 (0.8) 0
Symptoms suggestive of cardiac eventsb during 6 h first-dose observation
Patients with symptoms, n (%) 120 (3.0) 1 (3.2)c 1 (1.6)d 120 (8.9) 120 (100.0) 1 (2.6)
aOne of the patients had both, bradycardia and second-degree AV block and is therefore included in both groups
bCardiac symptoms are defined as the following MedDRA preferred terms: Angina pectoris, chest discomfort, dizziness, dyspnoea, dyspnoe exertional, fatigue,
palpitations, syncope, vertigo, vertigo positional, blurred vision
cFatigue and chest discomfort
dPalpitations
Table 3 Doses of study drug intake prior to discontinuation of
study drug
Fingolimod 0.5 mg
N = 50
Number of capsules taken n (%)
1 17 (34.0)
2 8 (16.0)
3–7 21 (42.0)
> 7 3 (6.0)
Missing 1 (2.0)
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degree AV blocks (Mobitz Type I and 2:1) were de-
tected in 1.6% of patients. Bradycardia and AV block
did not result in pre-syncope or syncope, demonstrat-
ing the benign and self-limiting nature of these car-
diac effects. Despite the large size of the cohort and
the transient occurrence of second-degree AV blocks
Type I and 2:1, no Mobitz II or third degree AV
blocks were observed. At visit 3, no patient had sec-
ond- or third-degree AV blocks and the lowest heart
rate was 43 bpm. The decrease in heart rate of pa-
tients with second-degree AV-blocks did not signifi-
cantly differ from that in patients without such an
event. Interestingly, the baseline mean heart rate of
patients who developed bradycardia during first dos-
ing was below 60, whereas in all other groups the
mean baseline heart rate was above 70. This could be
an indication that a patient with a low heart rate at
onset may be at risk to develop substantial
bradycardia.
Drug-related effects on myocardial repolarization (QT
interval >450/470 ms) were observed in five patients,
however, without a need for intervention. No patient re-
quired overnight monitoring due to QT interval prolonga-
tion > 500 ms, as warranted by the EU label. Although
single reports on spontaneous arrhythmias have been
published [11–16], no such events were observed in this
large cohort.
The results of START are consistent with previous
studies. Incidence of bradycardia and second-degree AV
blocks in previous studies were 1.3 to 1.4% (bradycar-
dia), 1.3 to 2.6% (Mobitz type I second-degree AV block,
Wenckebach) and 0.5 to 1.4% (2:1 second-degree AV
block) [7–10]. In a cohort of 625 healthy volunteers,
transient type I second-degree AV blocks (Wenckebach)
were observed in 14 (2.2%) individuals during nighttime.
Fig. 2 Patient disposition
Table 4 Heart rate dynamics by subgroup within 6 h post-dose
Number of patients Pre-dose
heart ratea (bpm)
Lowest post-dose
heart ratea (bpm)
Maximum decline in
heart ratea (bpm)
n (%) Mean (range) Mean (range) Mean (SD)
Fingolimod, N = 3951
Overall population
Overall population 3951 (100.0) 73.9 (45–132) 62.1 (31–101) 11.8 (8.47)
By time of lowest heart rate
Patients with lowest heart rate at < 6 h 3455 (87.4) 73.8 (45–132) 61.9 (31–101) 11.9 (8.42)
Patients with lowest heart rate at 6 h 496 (12.6) 74.6 (48–114) 63.5 (38–90) 11.1 (8.76)
p-valueb 0.0394
By presence of bradycardia
Patients with bradycardia 31 (0.8) 59.5 (46–80) 41.6 (31–44) 17.9 (8.30)
Patients without bradycardia 3920 (99.2) 74.0 (45–132) 62.2 (45–101) 11.7 (8.45)
p-valueb 0.0001
By presence of second-degree AV block
Patients with second-degree AV block 62 (1.6) 75.0 (56–95) 62.7 (42–83) 12.2 (8.12)
Patients without second-degree AV block 3889 (98.4) 73.8 (45–132) 62.1 (31–101) 11.8 (8.48)
p-valueb 0.691
aas measured by on-site study personnel
bStudents t-test
Limmroth et al. BMC Neurology  (2017) 17:11 Page 6 of 10
In three cases, AV blocks were also observed during day-
time [17]. The occurrence of AV blocks beyond the 6-
hour observation interval including nocturnal events
were investigated in the FREEDOMS II trial [8].
Fingolimod-induced second-degree AV blocks usually
occurred in the first six hours. The data indicated that
nighttime second-degree AV blocks were infrequent and
occurred in 0.6% of the patients receiving fingolimod
and in 2.0% of the placebo patients. These results under-
pin the interpretation that the incidence of AV blocks
during nighttime (>12 h after first dose) does not seem
higher than in the healthy population. However, as the
study cohorts differ, a valid comparison of incidence
rates would require adjustment for variations in patient
characteristics.
Except for one case accompanied by mild symptoms,
AV blocks observed in the START study were not associ-
ated with cardiac symptoms. Thus, the pathologic ECG
findings were usually not associated with any clinically
relevant event. Conversely, none of the few mild cardiac
symptoms observed showed a corresponding event in the
Holter ECG. In summary, Holter ECG data provide scien-
tifically valuable information of an in-depth understanding
of the electrocardiographic effects of fingolimod, but does
not help to identify patients at risk for clinically relevant
cardiac symptoms.
As lower degree AV conduction abnormalities also
occur in an otherwise healthy population without clinical
significance, they are generally not considered harmful
[18]. In general, type I second-degree AV blocks do not
require intervention as long as they are asymptomatic
[19]. On the contrary, third-degree and type II second-
degree AV blocks usually warrant intervention and even
constitute an indication for permanent pacemaker im-
plantation, which indicates their prognostic relevance
[19]. However, this approach does not apply to drug-
induced lower degree AV blocks, which are associated
with clinical concerns as they might predict more severe
AV conduction disturbances [18]. Drugs like beta-
blockers or calcium channel blockers are known for
their potential to induce deleterious AV conduction
abnormalities [18]. These disturbances can even relapse
after discontinuation of the inducing drug and may
require permanent use of pacemakers [20, 21].
The characteristics of second-degree AV blocks in the
START study indicate that the nature of AV conduction
effects of fingolimod might differ from other AV block
inducing drugs. For example, drug-induced AV blocks
are usually associated with significant slowing of heart
rate. However, in fingolimod-induced second-degree AV
Table 5 Second- and third-degree AV blocks during treatment
initiation
Fingolimod 0.5 mg
N = 3951
Patients with 12-lead ECG recording, n N = 3951
Patients with first-degree AV block, n (%) 280 (7.1)
Pre-dose 96 (2.7)
Post-dose 206 (5.8)
Patients with Holter ECG recording, n N = 3906
Patients with second-degree AV block, n (%) 62 (1.6)
Mobitz Type I (Wenckebach) 60 (1.5)a
2:1 18 (0.5)a
Mobitz Type II (Mobitz) 0
Patients with third-degree AV block, n (%) 0
aA patient might experience both Mobitz type I and 2:1 AV blocks during the
six-hour monitoring
Fig. 3 Changes in heart rate after the first dose of fingolimod. The time course of heart rate during the first 6 hours after fingolimod intake is
presented for the overall population, patients with bradycardia and patients with second-degree AV block (absolute values and SD)
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blocks no relevant decrease in heart rate was observed.
The mean minimal heart rate over ten consecutive beats
during AV block observed was 51.5 bpm. Furthermore,
the Holter ECGs did not show relevant pauses. Usually,
pauses are reported if they exceed 3 s in patients with
sinus rhythm. The longest pause recorded in association
with a second-degree AV block in this study was 2.6 s.
The absence of relevant pauses is underlined by the fact
that the events mostly remained asymptomatic. Finally,
none of the AV blocks progressed to a complete block
(third-degree AV block), as would have been expected
for drugs known to induce AV blocks (e.g. calcium chan-
nel blockers).
Therefore, AV blocks associated with fingolimod treat-
ment initiation can be considered as rather benign, self-
limiting and associated with an either low or virtually
non-existing propensity to progression to a complete AV
block. Although affected by fingolimod, overall AV con-
duction, which is determined by several ion currents (i.e.
particularly by calcium currents) [22, 23], remains pre-
served. In the present study, AV blocks were not pre-
ceded by excessive slowing of heart, what would be
expected, but followed increases in heart rate. This sug-
gests that slowing of AV conduction is due to a positive
rate-dependent electrophysiological effect of fingolimod.
A mild direct effect of fingolimod on the AV node was
postulated in a rodent study, where S1P1 receptor
mRNA expression was found to be high in the AV node.
Fingolimod prolonged the cycle length in isolated AV
node cells by 9% from 230 to 251 ms. Under patho-
logical conditions (such as ischemia/reperfusion), fingoli-
mod did not further prolong AV conduction.
Fingolimod-induced AV node conduction abnormalities
were discussed to be the result of a direct effect of the
Table 6 Most frequent (serious) adverse events
Fingolimod 0.5 mg N = 3951
Number of patients,
n (%)
Number of
events, n
Summary of adverse events
Any adverse event 1350 (34.17) 2207
Any serious adverse event 117 (2.96) 152
Any adverse event
leading to discontinuation
of study drug
38 (0.96) 69
Common adverse events (>1% in SOC/PT)
Nervous system disorders 403 (10.20) 464
Headache 199 (5.04) 205
Dizziness 72 (1.82) 73
MS relapse 58 (1.47) 59
General disorders and
administration site conditions
240 (6.07) 265
Fatigue 135 (3.42) 138
Cardiac disorders 231 (5.85) 263
AV block first degree 69 (1.75) 70
AV block second degree 65 (1.65) 67
Bradycardia 45 (1.14) 45
Gastrointestinal disorders 217 (5.49) 246
Nausea 91 (2.30) 92
Diarrhoea 52 (1.32) 52
Infections and infestations 170 (4.30) 178
Nasopharyngitis 78 (1.97) 78
Investigations 130 (3.29) 150
Blood and lymphatic disorders 115 (2.91) 140
Lymphopenia 73 (1.85) 74
Musculoskeletal and
connective tissue disorders
94 (2.38) 102
Skin and subcutaneous
tissue disorders
66 (1.67) 69
Psychiatric disorders 61 (1.54) 63
Vascular disorders 60 (1.52) 61
Respiratory, thoracic and
mediastinal disorders
59 (1.49) 60
Ear and labyrinth disorders 47 (1.19) 49
Common serious adverse events (>0.1% in SOC/PT)
Cardiac disorders 52 (1.32) 65
AV block second-degree 31 (0.78) 33
Bradycardia 15 (0.38) 15
AV block 5 (0.13) 5
Nervous system disorders 33 (0.84) 36
MS relapse 18 (0.46) 19
General disorders and administration
site conditions
7 (0.18) 7
Table 6 Most frequent (serious) adverse events (Continued)
Infections and infestations 7 (0.18) 7
Gastrointestinal disorders 6 (0.15) 8
Vascular disorders 6 (0.15) 6
Symptoms that might have resulted from cardiac events (at Visit 2)
Fatigue 68 (1.72)
Dizziness 26 (0.66)
Chest discomfort 8 (0.20)
Vertigo 7 (0.18)
Palpitations 7 (0.18)
Dyspnea 5 (0.13)
Angina pectoris 3 (0.08)
Blurred vision 2 (0.05)
Syncope 1 (0.03)
Exertional dyspnoe 1 (0.03)
PT preferred term, SOC system organ class
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drug on ion channels expressed in the AV node with
mild prolongation of AV conduction time [24].
Generally speaking, the effects of fingolimod on AV con-
duction have to be interpreted and weighed in the broader
context of its beneficial effects in a progressive disease
such as MS [1–3].
Conclusions
The results presented here are derived from an interim
analysis. The events identified by continuous ECG moni-
toring were associated neither with severe clinical symp-
toms nor with clinically relevant pauses or clinically
relevant drops in heart rate. Furthermore, patients with
clinical symptoms had no pathological findings on Hol-
ter ECG. Cardiac symptoms, if present, were rare, mild,
and occurred independently of the expected benign AV
conduction abnormalities and heart rate decline. ECG
monitoring did not detect any otherwise unforeseen
arrhythmias. In summary, clinically relevant cardiac
events were not associated with abnormalities on con-
tinuous ECG monitoring and conduction abnormalities
as demonstrated by Holter ECG usually remained clinic-
ally asymptomatic. Even without statistical evidence, the
results presented here suggest that continuous Holter
ECG monitoring after fingolimod first dose likely do not
add clinically relevant value to patient safety with re-
spect to bradycardia or conduction abnormalities in a
general RRMS population without cardiovascular
comorbidities.
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